伴有CLIP1-ALK融合基因晚期肺鳞癌1例  

A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene

作　　者：袁月 王征 聂鑫 张萍 李琳[1,2] Yue YUAN;Zheng WANG;Xin NIE;Ping ZHANG;Lin LI(Department of Oncology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Science;Graduate School of Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Pathology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Science,Beijing 100730,China)

机构地区：[1]国家老年医学中心,中国医学科学院老年医学研究所,北京医院肿瘤内科,北京100730 [2]中国医学科学院,北京协和医学院研究生院,北京100730 [3]国家老年医学中心,中国医学科学院老年医学研究所,北京医院病理科,北京100730

出　　处：《中国肺癌杂志》2022年第9期696-700,共5页Chinese Journal of Lung Cancer

摘　　要：间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因是非小细胞肺癌的重要的肿瘤驱动基因,约占非小细胞肺癌患者的5%左右,其中97%为肺腺癌患者。自2007年首次在肺腺癌患者中发现棘皮动物微管相关蛋白样4(echinoderm microtubule-associated protein-like 4,EML4)-ALK融合以来,多种ALK融合伴侣相继被检测出来。本例晚期肺鳞癌患者通过二代测序(next generation sequencing,NGS)检测到CLIP1-ALK融合基因,并于2021年5月5日开始先后口服阿来替尼、恩沙替尼治疗,阿来替尼治疗有效,但于2021年9月30日去世。本文报道了接受ALK抑制剂治疗的CLIP1-ALK融合基因的肺鳞癌患者,并对其疗效进行讨论。Anaplastic lymphoma kinase(ALK)fusion gene is an important tumor driver gene of non-small cell lung cancer,accounting for about 5%of patients with non-small cell lung cancer,of which 97%are patients with lung adenocarcinoma.Since the first discovery of echinoderm microtubule associated protein-like 4(EML4)-ALK fusion in patients with lung adenocarcinoma in 2007,a variety of ALK fusion partners have been detected.CLIP1-ALK fusion gene was detected by next generation sequencing(NGS)in this patient with advanced lung squamous cell carcinoma,and Alectinib and Ensartinib were taken orally on May 5,2021.Aletinib was effective for this patient but the patients died on September 30,2021.This is a report of lung squamous cell carcinoma patients with CLIP1-ALK fusion gene treated with ALK inhibitors.

关 键 词：ALK融合基因 肺肿瘤 ALK抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]